The Journal of Immunology, Vol 144, Issue 3 998-1003, Copyright © 1990 by American Association of Immunologists

ARTICLES

Resistance of cytolytic lymphocytes to perforin-mediated killing. Inhibition of perforin binding activity by surface membrane proteins

SB Jiang, DM Ojcius, PM Persechini and JD Young
Laboratory of Cellular Physiology and Immunology, Rockefeller University, New York, NY 10021.

The mechanism whereby cytolytic lymphocytes protect themselves from killing mediated by their own cytotoxic protein, perforin, was studied. By using a competition assay, we demonstrated that the resistance of cells to perforin-mediated cytolysis is inversely correlated with their ability to absorb perforin, with tumor cells and noncytotoxic lymphocytes that are susceptible to perforin-mediated lysis being able to absorb perforin from the supernatant much better than CTL. The evidence implies that there is molecule on cytolytic lymphocytes that interferes with perforin-binding activity, resulting in the inability of perforin to lyse these cells. The molecule is most likely a surface protein or complex of proteins because its activity decreases after CTL treatment with the proteolytic enzymes trypsin and papain, and the activity can be recovered by incubation of the treated CTL cells at 37 degrees C for 6 h. The recovery can be blocked by emetine, cycloheximide, and actinomycin D, inhibitors of protein and RNA/DNA synthesis. The protein contains carbohydrate groups that play an important role in the function of the protein, as indicated by the fact that inhibition of glycosylation by tunicamycin and cleavage of sialic acid from the protein with neuraminidase result in a significant increase of perforin binding to CTL. Cross-linkage of CTL membrane proteins with glutaraldehyde and formaldehyde and blockage of the functional domains of the protein with an antiserum against CTL also inhibit the activity of this protein. Temperature-dependence studies that allow for a dissociation of the binding and pore-forming stages of perforin-mediated hemolysis suggest that the protective protein interferes at the perforin-binding stage.

This article has been cited by other articles:

				I. Moisini, P. Nguyen, L. Fugger, and T. L. Geiger Redirecting Therapeutic T Cells against Myelin-Specific T Lymphocytes Using a Humanized Myelin Basic Protein-HLA-DR2-{zeta} Chimeric Receptor J. Immunol., March 1, 2008; 180(5): 3601 - 3611. [Abstract] [Full Text] [PDF]

				K. Baran, A. Ciccone, C. Peters, H. Yagita, P. I. Bird, J. A. Villadangos, and J. A. Trapani Cytotoxic T Lymphocytes from Cathepsin B-deficient Mice Survive Normally in Vitro and in Vivo after Encountering and Killing Target Cells J. Biol. Chem., October 13, 2006; 281(41): 30485 - 30491. [Abstract] [Full Text] [PDF]

				T. Azuma, T. Otsuki, K. Kuzushima, C. J. Froelich, S. Fujita, and M. Yasukawa Myeloma Cells Are Highly Sensitive to the Granule Exocytosis Pathway Mediated by WT1-Specific Cytotoxic T Lymphocytes Clin. Cancer Res., November 1, 2004; 10(21): 7402 - 7412. [Abstract] [Full Text] [PDF]

				D. J. Mekala and T. L. Geiger Functional Segregation of the TCR and Antigen-MHC Complexes on the Surface of CTL J. Immunol., October 15, 2003; 171(8): 4089 - 4095. [Abstract] [Full Text] [PDF]

				K. N. Balaji, N. Schaschke, W. Machleidt, M. Catalfamo, and P. A. Henkart Surface Cathepsin B Protects Cytotoxic Lymphocytes from Self-destruction after Degranulation J. Exp. Med., August 19, 2002; 196(4): 493 - 503. [Abstract] [Full Text] [PDF]

				C. Lehmann, M. Zeis, N. Schmitz, and L. Uharek Impaired binding of perforin on the surface of tumor cells is a cause of target cell resistance against cytotoxic effector cells Blood, July 15, 2000; 96(2): 594 - 600. [Abstract] [Full Text] [PDF]

				C. Berthou, J.-F. Bourge, Y. Zhang, A. Soulie, D. Geromin, Y. Denizot, F. Sigaux, and M. Sasportes Interferon-gamma -induced membrane PAF-receptor expression confers tumor cell susceptibility to NK perforin-dependent lysis Blood, April 1, 2000; 95(7): 2329 - 2336. [Abstract] [Full Text] [PDF]